- Home
- GNRC vs MRNA Comparison
GNRC vs MRNA Comparison
Compare GNRC & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNRC
- MRNA
- Stock Information
- Founded
- GNRC 1959
- MRNA 2010
- Country
- GNRC United States
- MRNA United States
- Employees
- GNRC N/A
- MRNA N/A
- Industry
- GNRC Metal Fabrications
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GNRC Consumer Discretionary
- MRNA Health Care
- Exchange
- GNRC Nasdaq
- MRNA Nasdaq
- Market Cap
- GNRC 8.9B
- MRNA 9.2B
- IPO Year
- GNRC 2010
- MRNA 2018
- Fundamental
- Price
- GNRC $151.34
- MRNA $24.62
- Analyst Decision
- GNRC Buy
- MRNA Hold
- Analyst Count
- GNRC 18
- MRNA 15
- Target Price
- GNRC $188.72
- MRNA $36.69
- AVG Volume (30 Days)
- GNRC 1.4M
- MRNA 12.2M
- Earning Date
- GNRC 10-29-2025
- MRNA 11-06-2025
- Dividend Yield
- GNRC N/A
- MRNA N/A
- EPS Growth
- GNRC 9.08
- MRNA N/A
- EPS
- GNRC 5.26
- MRNA N/A
- Revenue
- GNRC $4,352,444,000.00
- MRNA $2,232,000,000.00
- Revenue This Year
- GNRC $2.33
- MRNA N/A
- Revenue Next Year
- GNRC $10.85
- MRNA $10.38
- P/E Ratio
- GNRC $28.77
- MRNA N/A
- Revenue Growth
- GNRC 5.52
- MRNA N/A
- 52 Week Low
- GNRC $99.50
- MRNA $23.04
- 52 Week High
- GNRC $203.25
- MRNA $48.92
- Technical
- Relative Strength Index (RSI)
- GNRC 34.47
- MRNA 45.38
- Support Level
- GNRC $149.86
- MRNA $23.04
- Resistance Level
- GNRC $163.93
- MRNA $27.10
- Average True Range (ATR)
- GNRC 8.57
- MRNA 1.61
- MACD
- GNRC -1.81
- MRNA -0.02
- Stochastic Oscillator
- GNRC 2.97
- MRNA 26.54
About GNRC Generac Holdlings Inc.
Generac designs and manufactures power generation equipment serving residential, commercial, and industrial markets. It offers standby generators, portable generators, lighting, outdoor power equipment, and a suite of clean energy products. Sales generated in the United States account for the majority of total sales.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.